secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYTOKINETICS INC (CYTK)
CIK:        0001061983
Form:       8-K
Filed at:   2025-03-10T23:59:59+00:00
Accession:  0000950170-25-035914
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytokinetics: FDA won't hold adcom for aficamten NDA; Late Cycle meeting set for June 2025
--------------------------------------------------------------------------------

- Cytokinetics completed midcycle review with FDA for aficamten NDA treating obstructive hypertrophic cardiomyopathy.
- FDA informed Cytokinetics it does not plan to convene an advisory committee meeting for the aficamten NDA.
- Late Cycle meeting with FDA expected in June 2025; company maintains expectation for differentiated label and risk mitigation if approved.
- Cytokinetics does not plan to share detailed updates on FDA communications beyond this update.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061983/000095017025035914/0000950170-25-035914-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061983/000095017025035914/cytk-20250310.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-035914

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer